Evidence map›Paper›PMID 28081708›Full record

ArticleGenome biology2017

Identifying aggressive prostate cancer foci using a DNA methylation classifier.

Kamilla Mundbjerg, Sameer Chopra, Mehrdad Alemozaffar, Christopher Duymich, Ranjani Lakshminarasimhan, Peter W Nichols, Manju Aron, Kimberly D Siegmund, Osamu Ukimura, Monish Aron and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genome biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Clonal evaluation of prostate cancer molecular heterogeneity in biopsy samples by dual immunohistochemistry and dual RNA in situ hybridization.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Kamilla MundbjergUSC Institute of Urology and the Catherine & Joseph Aresty Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA.
Sameer ChopraUSC Institute of Urology and the Catherine & Joseph Aresty Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA.
Mehrdad AlemozaffarUSC Institute of Urology and the Catherine & Joseph Aresty Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA.
Christopher DuymichUSC Institute of Urology and the Catherine & Joseph Aresty Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA.
Ranjani LakshminarasimhanUSC Institute of Urology and the Catherine & Joseph Aresty Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA.
Peter W NicholsDepartment of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA.
Manju AronDepartment of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA.
Kimberly D SiegmundDepartment of Preventive Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA.
Osamu UkimuraUSC Institute of Urology and the Catherine & Joseph Aresty Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA.
Monish AronUSC Institute of Urology and the Catherine & Joseph Aresty Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA.
Mariana SternDepartment of Preventive Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA.
Parkash GillDepartment of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA.
John D CarptenDepartment of Translational Genomics, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA.
Torben F ØrntoftDepartment of Molecular Medicine, Aarhus University Hospital, 8200, Aarhus N, Denmark.
Karina D SørensenDepartment of Molecular Medicine, Aarhus University Hospital, 8200, Aarhus N, Denmark.
Daniel J WeisenbergerDepartment of Biochemistry and Molecular Biology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA.
Peter A JonesUSC Institute of Urology and the Catherine & Joseph Aresty Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA.
Vinay DuddalwarDepartment of Radiology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA.
Inderbir GillUSC Institute of Urology and the Catherine & Joseph Aresty Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA. igill@med.usc.edu.
Gangning LiangUSC Institute of Urology and the Catherine & Joseph Aresty Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90089, USA. gliang@usc.edu.ORCID 0000-0001-8664-922X

Funding

MECHANISMS OF DE NOVO METHYLATION IN CANCERR01CA082422 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI JONES, PETER A · 1999 to 2016
$5.1M
Using DNA methylation markers to improve the predictive accuracy and utility of needle biopsiesfor determining prostate cancer aggressivenessR21CA201865 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GILL, INDERBIR, LIANG, GANGNING · 2016 to 2017
$395k
NCI NIH HHS R01 CA082422NCI NIH HHS R21 CA201865
6 · The paper itself

Abstract

backgroundSlow-growing prostate cancer (PC) can be aggressive in a subset of cases. Therefore, prognostic tools to guide clinical decision-making and avoid overtreatment of indolent PC and undertreatment of aggressive disease are urgently needed. PC has a propensity to be multifocal with several different cancerous foci per gland.

resultsHere, we have taken advantage of the multifocal propensity of PC and categorized aggressiveness of individual PC foci based on DNA methylation patterns in primary PC foci and matched lymph node metastases. In a set of 14 patients, we demonstrate that over half of the cases have multiple epigenetically distinct subclones and determine the primary subclone from which the metastatic lesion(s) originated. Furthermore, we develop an aggressiveness classifier consisting of 25 DNA methylation probes to determine aggressive and non-aggressive subclones. Upon validation of the classifier in an independent cohort, the predicted aggressive tumors are significantly associated with the presence of lymph node metastases and invasive tumor stages.

conclusionsOverall, this study provides molecular-based support for determining PC aggressiveness with the potential to impact clinical decision-making, such as targeted biopsy approaches for early diagnosis and active surveillance, in addition to focal therapy.

Indexed as

DNA MethylationQuantitative Trait LociBiomarkers, TumorBiopsyCluster AnalysisDisease ProgressionEpigenesis, GeneticEpigenomicsGene Expression ProfilingHumansLymphatic MetastasisMaleNeoplasm MetastasisNeoplasm StagingPrognosisProstatic NeoplasmsBiomarkers, TumorAggressivenessDNA methylationMultifocalProstate cancer

Identifiers

PMID28081708
PMCPMC5234101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.